The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Economic burden of inadequate management of allergic diseases in the European Union: a GA2LEN review
Open accessAbstract
Background: In the European Union (EU), between 44 and 76 million individuals of the 217 million EU employees suffer from allergic disease of the airways or the skin. Up to 90% of these persons are untreated or insufficiently treated. This has major socio‐economic consequences such as absence from work (absenteeism), particularly reduced productivity at work (presenteeism). Methods: We used published literature and online statistical information from Eurostat and Eurofound to assess the costs of allergic disease to society. Results: Allergies have an impact on direct, indirect, intangible and opportunity costs. Most importantly, for the EU, avoidable indirect costs per patient insufficiently treated for allergy range between €55 and €151 billion per annum due to absenteeism and presenteeism, that is, €2405 per untreated patient per year. On the other hand, appropriate therapy for allergic diseases is available at comparatively low costs at an average of €125 per patient annually, equalling only 5% of the costs of untreated disease, allowing potential savings of up to €142 billion. Conclusions: A better care for allergies based on guideline‐based treatment would allow Europe's economy substantial savings. In addition, allergies have an impact on learning and performance at school and university, leading to opportunity costs for society. This cannot be calculated moneywise but will have an impact in a modern knowledge‐based society. Still allergies are trivialized in society, noting that the costs of therapy are paid by patients and healthcare services, whereas economic savings are made by employers and society. A change of this mindset is urgently needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence and rate of diagnosis of allergic rhinitis in Europe
Bauchau, V., & Durham, S. R. (2004) · European Respiratory Journal · doi:10.1183/09031936.04.00013904 · Cited by 1,022
Risk of first‐generation H 1 ‐antihistamines: a GA 2 LEN position paper
Church, M. K., Maurer, M., Simons, F. E. R., Bindslev‐Jensen, C., Van Cauwenberge, P., Bousquet, J., Holgate, S. T., & Zuberbier, T. (2010) · Allergy · doi:10.1111/j.1398-9995.2009.02325.x · Cited by 440
Self-citationWalker, S., Khan-Wasti, S., Fletcher, M., Cullinan, P., Harris, J., & Sheikh, A. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.03.034 · Cited by 431
The Atopic March: Progression from Atopic Dermatitis to Allergic Rhinitis and Asthma
Zheng, T., Yu, J., Oh, M. H., & Zhu, Z. (2011) · Allergy, Asthma and Immunology Research · doi:10.4168/aair.2011.3.2.67 · Cited by 425
Patient perspectives on the management of atopic dermatitis
Zuberbier, T., Orlow, S. J., Paller, A. S., Taïeb, A., Allen, R., Hernanz-Hermosa, J. M., Ocampo-Candiani, J., Cox, M., Langeraar, J., & Simon, J. C. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.02.031 · Cited by 339
Self-citationUnmet needs in severe chronic upper airway disease (SCUAD)
Bousquet, J., Bachert, C., Canonica, G. W., Casale, T. B., Cruz, A. A., Lockey, R. J., & Zuberbier, T. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.06.027 · Cited by 227
Self-citationBachert, C., Bousquet, J., Canonica, G. W., Durham, S. R., Klimek, L., Mullol, J., Van Cauwenberge, P. B., & Van Hammée, G. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.05.070 · Cited by 215 · cited 1×
“Thus, as an input parameter on purpose, 3 days absenteeism was chosen, which is lower than the published values, and the calculated €528 per person per annum is in line with questionnaire-based results of allergic rhinitis sufferers in France, where €543 per person per annum was calculated (11).”
ResultAllergic rhinitis and the common cold – high cost to society
Hellgren, J., Cervin, A., Nordling, S., Bergman, A., & Cardell, L. O. (2010) · Allergy · doi:10.1111/j.1398-9995.2009.02269.x · Cited by 183
Undertreatment of rhinitis symptoms in Europe: findings from a cross‐sectional questionnaire survey
Maurer, M., & Zuberbier, T. (2007) · Allergy · doi:10.1111/j.1398-9995.2007.01367.x · Cited by 161
Self-citationPrevalence of Allergic Sensitization versus Allergic Rhinitis Symptoms in an Unselected Population
Blomme, K., Tomassen, P., Lapeere, H., Huvenne, W., Bonny, M., Acke, F. R. E., Bachert, C., & Gevaert, P. (2012) · International Archives of Allergy and Immunology · doi:10.1159/000339853 · Cited by 125
Cited by
Akdis (2020) · doi:10.1111/pai.13189 · Cited by 320
Phenotypes and endotypes of rhinitis and their impact on management: a PRACTALL report
Papadopoulos, N. G., Bernstein, J. A., Demoly, P., Dykewicz, M., Fokkens, W., Hellings, P. W., Peters, A. T., Rondon, C., Togias, A., & Cox, L. S. (2015) · Allergy · doi:10.1111/all.12573 · Cited by 182
MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis
Bousquet, J., Schünemann, H. J., Hellings, P. W., Arnavielhe, S., Bachert, C., Bedbrook, A., Bergmann, K.-C., Bosnic-Anticevich, S., Brozek, J., Calderon, M., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.03.025 · Cited by 168
Self-citationTOTALL: high cost of allergic rhinitis—a national Swedish population-based questionnaire study
Cardell, L.-O., Olsson, P., Andersson, M., Welin, K.-O., Svensson, J., Tennvall, G. R., & Hellgren, J. (2016) · npj Primary Care Respiratory Medicine · doi:10.1038/npjpcrm.2015.82 · Cited by 149
Colás, C., Brosa, M., Antón, E., Montoro, J., Navarro, A., Dordal, M. T., Dávila, I., Fernández‐Parra, B., Ibáñez, M. D. P., Lluch‐Bernal, M., et al. (2017) · Allergy · doi:10.1111/all.13099 · Cited by 101
Metadata
- Authors
- Zuberbier, T., Lötvall, J., Simoens, S., Subramanian, S. V., & Church, M. K.
- Venue
- Allergy
- Publisher
- Wiley
- Published
- 2014-08
- Volume
- 69
- Issue
- 10
- Pages
- 1275-1279
- ISSN
- 0105-4538 (ISSN-L)
- 1398-9995
- OpenAlex
- W2038121739
- Cited by
- 395
- References
- 14
- FWCI
- 17.52
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Economic burden of inadequate management of allergic diseases in the European Union: a GA2LEN review. https://app.cochat.ai/papers/10.1111/all.12470
- The paper
- Zuberbier, T., Lötvall, J., Simoens, S., Subramanian, S. V., & Church, M. K. (2014). Economic burden of inadequate management of allergic diseases in the European Union: a GA2LEN review. Allergy. https://doi.org/10.1111/all.12470
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
